Table 3.
Industry TRPV antagonist pipeline.
| Antagonist | |||
|---|---|---|---|
| ABT-102 [ClinicalTrials.gov identifier: NCT00854659] | Abbott Labs | Inflammatory pain/tissue injury | One phase I completed; |
| no active studies posted | |||
| AMG-334 [ClinicalTrials.gov identifiers: NCT01723514, NCT01688739] | Amgen | Subcutaneous or intravenous for migraine | Phase I, currently enrolling |
| AMG-517 (no studies found on ClinicalTrials.gov) [Kym et al. 2009] | Amgen | Pain | |
| AZD-1386 [ClinicalTrials.gov identifiers: NCT00672646, NCT00832169, NCT00878501, NCT00714337, NCT00672646, NCT00690079, NCT00945178, NCT00692146, NCT00976534] | Astra Zeneca | A total of 11 studies, 6 complete, 3 terminated, 2 in gastroesophageal reflux disease (not included in this table) | No current studies posted |
| DWP-05195 [ClinicalTrials.gov identifiers: NCT01094834, NCT01557010, NCT00969787]. | Daewoong Pharmaceuticals | One phase II study in PHN ongoing, two phase I studies | |
| GRC-6211a [Szallasi and Shera, 2012] | Glenmark/Lilly | Neuropathic pain, phase I and osteoarthritis phase II. | |
| GRC-17535 [ClinicalTrials.gov identifier: NCT01556152, NCT01726413] | Glenmark | Two phase II trials in diabetic peripheral polyneuropathy neuropathy | One withdrawn, one currently enrolling patients |
| GRC-15300b [Glenmark Pharmaceuticals 2013] | Glenmark | Phase I and phase II in neuropathic pain (TRPV-3 agonist) | Unknown status |
| MK-2295 [ClinicalTrials.gov identifier: NCT00387140] | Merck/Neurogen | One study in dental pain | |
| PHE-377c [Szallasi and Shera, 2012] | PharmEste | Phase I, neuropathic pain | |
| PHE-575c [Szallasi and Shera, 2012] | PharmEste | TRPV1 and TRPA1 antagonist, neuropathic pain | Preclinical and phase I |
| SB-705498 (ClinicalTrials.gov identifiers: NCT00269022, NCT00281684, NCT00907933, NCT00461682, NCT00731250, NCT01673529] | GSK | Intranasally, topically, orally: 10 studies, 1 in migraines, 1 in tooth extraction, 1 in rectal pain, 3 phase III (4 in allergic rhinitis and 1 in cough not included) | Phase I and II completed; no active studies posted |
| MR-1817 [ClinicalTrials.gov identifier: NCT00960180]. | Mochida | Phase I | No active studies posted |
| JNJ-39439335 [ClinicalTrials.gov identifiers: NCT01631487, NCT01343303, NCT01454245, NCT01006304, NCT00933582] | J&J | Phase I | Phase I studies completed; no active studies posted |
TRPA1, transient receptor potential cation channel, subfamily A, member 1; TRPV1, transient receptor potential vanilloid-1; PHN, post-herpetic neuropathy
a
Mentioned by Szallasi and Shera [2012]; not found on ClinicalTrials.gov or on the Glenmark website.
b
Listed on the Glenmark website, see footnote; not listed on ClinicalTrials.gov
c
Mentioned by Szallasi and Shera [2012] and on the PharmEste website (http://www.pharmeste.com/home.asp?op=interna&id=2&id_pag=10&tit=Pipeline); not found on ClinicalTrials.gov.